ArticleScientific reports2025
Clinical and microbiological analysis of risk factors for breakthrough bloodstream infection during Tigecycline Therapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Nationwide Burden of Metallo-β-Lactamase Genes in Brazilian ClinicalAntibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundTigecycline is widely used to treat a variety of bacterial infections despite concerns regarding increased mortality in severe infections. Previous case reports have documented breakthrough bloodstream infections (BSI) during tigecycline therapy. This study aimed to investigate the incidence of, and risk factors for, breakthrough BSI during tigecycline monotherapy.
methodsA retrospective matched case-control study was conducted in a 2700-bed tertiary referral center, involving patients who received tigecycline monotherapy. Patients with breakthrough BSI (1:1) were matched with controls without breakthrough BSI based on age, sex, and date of tigecycline therapy.
resultsOf 4505 patients treated with tigecycline, 115 (2.6%, 95% confidence interval 2.1 to 3.1%) developed breakthrough BSI. The most frequently identified pathogen in breakthrough BSI was Klebsiella pneumoniae (22.8%), followed by Candida species (17.1%), Pseudomonas aeruginosa (16.3%), and Acinetobacter baumannii (14.6%). Of the K. pneumoniae and A. baumannii isolates for which tigecycline susceptibility results were available, 50% and 23%, respectively, were tigecycline-resistant (MIC > 2 mg/L). Intraabdominal (33.9%), catheter-related (30.4%), and hepatobiliary (19.1%) infections were the main sources of breakthrough BSI. In multivariable analysis, independent risk factors for breakthrough BSI during tigecycline therapy were liver cirrhosis (adjusted odds ratio [aOR], 3.09), indwelling catheter (aOR, 3.42), previous Candida colonization (aOR, 14.95), and previous multi-drug resistant bacteria colonization (aOR, 10.30).
conclusionIn cases where there is a high suspicion of breakthrough BSI during tigecycline therapy, meticulous management and prudent selection of empirical antibiotics are crucial due to the diverse range of causative microorganisms involved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.